Navigation Links
Reducing HIV Transmission

Researchers report encouraging results from a follow-up study of a new drug aimed at reducing the transmission of HIV from infected mothers to their newborn children.//

Health officials estimate in 2002 about 800,000 children around the world were infected with HIV through mother-to-child transmission. More than 90 percent of these cases occurred in underdeveloped nations.

The incidence is much lower in developed countries because HIV-infected mothers are routinely treated with the anti-HIV drug zidovudine during pregnancy and labor, and their infants receive the drug during the first six weeks of life. This treatment, however, is generally considered too complicated for use in less developed countries.

In 1999, investigators, working with health professionals in Uganda, reported positive results from the use of a new drug called nevirapine when administered to infected mothers once during labor and to infants one time within 72 hours of birth. The treatment was compared to a treatment regimen with zidovudine given at labor onset and every three hours until delivery to the mother and twice daily to their infants for seven days.

The current study followed the infants up to 18 months of age. Results showed the 8.2-percent reduction in HIV transmission that was seen for infants on nevirapine at six to eight weeks in the original study was sustained at 18 months. They conclude, "This simple, inexpensive, well-tolerated regimen has the potential to significantly decrease HIV-1 perinatal transmission in less developed countries."

However, researchers say resistance to single-agent anti-HIV drugs often develops and suggests more needs to be done to prevent transmission of HIV from infected mothers to their newborn children.

Suboptimum single-agent and double-agent prophylaxis protocols no longer have a justifiable place in the front lines of the global struggle against HIV/AIDS. It is up to all of us to focus on developm ent of equitable distribution and effective use of these agents now.
'"/>




Related medicine news :

1. Reducing Lung Cancer Risk
2. Reducing the risk for type 2 diabetes
3. Reducing Medication Errors
4. Reducing Pain from Knee Surgery
5. Reducing Pain From Knee Surgery
6. Reducing The After Effects of Tonsillectomy
7. Antiparasitic Drug Effective In Reducing Seizures In Neurocysticercosis Patients
8. Reducing Number Of Cigarettes Not Enough
9. Drug Found Effective In Reducing Vertebral Fractures In Women
10. Reducing TB With Ultraviolet Light
11. Reducing The Risk Of Fractures After a Heart Transplant
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2017)... , ... June 25, 2017 , ... CareSet Labs released ... in New Orleans. This is a new, greatly improved version of the Doctor Referral ... (FOIA) requests by Fred Trotter and subsequently called the the “Doctor Referral Dataset” as ...
(Date:6/25/2017)... ... June 25, 2017 , ... June is Men’s Health Month and the ... common cancer among men in the U.S. and the third most common cause of cancer ... that one man in seven will be diagnosed with prostate cancer during his lifetime. ...
(Date:6/24/2017)... (PRWEB) , ... June 24, 2017 , ... ... in Erie, PA at the Sheraton Erie Bayfront and Erie Convention Center on ... based medicine experience, exhibits, a student quiz bowl, award and scholarship presentations, and ...
(Date:6/24/2017)... ... June 24, 2017 , ... The weather is heating up and ... and business owners should be aware that the summer months provide more than warmer ... locks and keys can be negatively affected from direct exposure to the sun. When ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island Quality ... Management Alerts and Dashboards, an innovative new service enabling healthcare providers to proactively ... Management Alerts and Dashboards provide near real-time data about patients admitted to and/or ...
Breaking Medicine News(10 mins):
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
(Date:5/30/2017)... Corp. (NASDAQ: DRIO), a leading global digital health company with mobile ... presenting at the 7th annual LD Micro Invitational on Tuesday, June ... of DarioHealth will be giving the presentation and meeting with investors. ... 7th, 2017 at the Luxe Sunset Bel Air Hotel and will ... About LD Micro LD Micro was founded ...
(Date:5/29/2017)... TEL AVIV, Israel, May 29, 2017  Cellect Biotechnology ... of innovative technology which enables the functional selection of ... financial results for the first quarter ended March 31 ... pleased with our accomplishments in the first quarter of ... the first quarter, we announced the treatment of the ...
Breaking Medicine Technology: